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In 1990, Fearon and Vogelstein proposed that a series of specific
mutations occurs in the development of colorectal cancers. These
mutations are associated with histological features of tumours.
Several postulates of the model appear to be correct, particularly
the step-wise accumulation of genetic changes and the involve-
ment of mutations in APC and TP53 (Ilyas and Tomlinson, 1996).
Since this model was published, it is now recognized that muta-
tions within other genes are also involved. Moreover, there is
evidence suggesting that some colorectal cancers develop along
different molecular pathways (Ilyas and Tomlinson, 1996).
Bcl10 is a recently identified gene, which appears to be
commonly involved in the pathogenesis of a wide range of malig-
nancies, including two colorectal cancer cell lines (Willis et al,
1999). To investigate whether Bcl10 is commonly involved in
colorectal carcinogenesis we have analysed 132 colorectal adeno-
carcinomas and eight colorectal cancer cell lines for mutations.
MATERIALS AND METHODS
Tumour specimens
Paired blood and tumour specimens were collected from 132
patients with histologically proven colorectal adenocarcinomas
(76 paraffin-embedded and 56 fresh-frozen samples) and eight
colorectal cancer cell lines. Tumour samples were obtained with
informed consent and ethical review board approval. The
following clinical data were also available from patients: patient
sex, age at presentation, tumour site and replication error (RER)
status.
DNA extraction
DNA was salt extracted from EDTA blood samples using a
standard sucrose lysis method. Cell line and fresh-frozen tumour
DNAs were extracted using the Nucleon kit (Anachem). Formalin-
fixed and paraffin-embedded sections of colorectal cancers,
prepared for routine histopathology, were used for DNA prepara-
tion. Three times 15-mm sections were cut onto double-sided, clear
adhesive tape and placed on glass slides. These were lightly
stained with toluidine blue and regions containing at least 60%
tumour microdissected. Tumours were digested in buffer, 10 mM
Tris–HCl (pH 7.5), 1 mM EDTA, 15% (w/v) sodium dodecyl
sulphate (SDS) and 500 mg ml–1 proteinase K, for 16 h at 56°C.
DNA was then precipitated with sodium acetate and ethanol
following phenol–chloroform extraction.
Mutation screening
The search for mutations in each of the three exons of Bcl10
was performed using conformation-sensitive gel electrophoresis
(CSGE). For the paraffin-embedded carcinomas, the full coding
sequence of Bcl10 was amplified by five different PCR reactions
using published primer sequences (Willis et al, 1999). CSGE was
performed as reported by Gangulay et al (1993). All samples with
band shifts were sequenced in duplicate and in forward and
reverse orientations after re-amplification of the appropriate exon
from genomic DNA in the polymerase chain reaction (PCR).
Purified PCR products were sequenced using the ABI Ready
Reaction Dye Terminator Cycle Sequencing Kit and the ABI377
Prism Sequencer. For the cell line and fresh-frozen tumour
samples, exons 2A, 2B and 3A were amplified, so as to include
both the region of the genes in which almost all somatic Bcl10
mutations had been reported and the polyadenine tracts in the
gene. These samples were screened by single-strand conformation
polymorphism (SSCP) and by direct genotyping using the ABI377
sequencer to search for insertions and deletions.
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One interesting feature of the Bcl10 gene is that it harbours two
polyadenine tracts (Willis et al, 1999). One of the two Bcl10 muta-
tions in colorectal cancer lines reported by Willis et al (1999) was
an insertion of A within one of these polyadenine tracts. These
repeating elements in genes can be prone to a high rate of mutation
if there is defective mismatch repair, and this is observed in RER-
positive tumours at loci such as transforming growth factor (TGF)-
b type II receptor and Bax (Parsons et al, 1995). To examine the
possibility that Bcl10 may be preferentially mutated in mismatch
repair deficient cancers, 49 of the tumours and cell lines analysed
were known to be RER-positive and of these ten were from indi-
viduals harbouring germline mutations in hMLH1 or hMSH2.
In the none of the 132 tumour samples was any pathogenic
mutation identified, although two polymorphic variants were
detected. One of these was a synonymous G to C substitution
within codon 8 encoding leucine, present in 47/76 of the cancers
(62%) analysed at this site. The other polymorphism, detected in
25/76 cancers (39%), was a G to C base substitution within intron
1 of the gene at nucleotide 58. There was no difference in the
frequency of either of these variants between RER-positive and
RER-negative colorectal cancers. One previously reported
frameshift mutation (Willis et al, 1999) was found in the RER+
cell line LOVO at one of the polyadenine tracts, as a heterozygote
with the wild-type allele, LOVO harbours a mutation in hMSH2
and shows an exceptionally high level of instability at poly-
nucleotide repeats. In the light of the results from other tumours
and cell lines, there must be severe doubts that the Bcl10 mutation
in LOVO has any functional significance.
We cannot entirely exclude the possibility that a minority of
Bcl10 mutations have been missed, or cannot be detected by a
PCR-based approach. However, under test conditions we have
found that CSGE can detect all small insertions and deletions and
90% of single-base substitutions, and that SSCP can detect about
80% of all small-scale mutations. Confirmation of the efficiency
of CSGE and SSCP techniques was provided by the fact that we
were able to demonstrate a number of single-base substitution
polymorphisms within the gene and the previously described
mutation in LOVO. Therefore, it is improbable that we have failed
to detect any coding mutations. This study provides strong
evidence that Bcl10 is not involved in colorectal carcinogenesis.
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